234 related articles for article (PubMed ID: 35732347)
1. BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma.
Kremenovic M; Chan AA; Feng B; Bäriswyl L; Robatel S; Gruber T; Tang L; Lee DJ; Schenk M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732347
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular insights into BCG immunotherapy for melanoma.
Kremenovic M; Schenk M; Lee DJ
J Intern Med; 2020 Dec; 288(6):625-640. PubMed ID: 32128919
[TBL] [Abstract][Full Text] [Related]
3. Photochemically-Mediated Inflammation and Cross-Presentation of
Waeckerle-Men Y; Kotkowska ZK; Bono G; Duda A; Kolm I; Varypataki EM; Amstutz B; Meuli M; Høgset A; Kündig TM; Halin C; Sander P; Johansen P
Front Immunol; 2022; 13():815609. PubMed ID: 35173729
[TBL] [Abstract][Full Text] [Related]
4.
Lardone RD; Chan AA; Lee AF; Foshag LJ; Faries MB; Sieling PA; Lee DJ
Front Immunol; 2017; 8():965. PubMed ID: 28848560
[TBL] [Abstract][Full Text] [Related]
5. Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.
Aris M; Bravo AI; Garcia Alvarez HM; Carri I; Podaza E; Blanco PA; Rotondaro C; Bentivegna S; Nielsen M; Barrio MM; Mordoh J
Front Immunol; 2019; 10():2213. PubMed ID: 31620131
[TBL] [Abstract][Full Text] [Related]
6. HDAC9 deficiency promotes tumor progression by decreasing the CD8
Ning Y; Ding J; Sun X; Xie Y; Su M; Ma C; Pan J; Chen J; Jiang H; Qi C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554611
[TBL] [Abstract][Full Text] [Related]
7. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
[TBL] [Abstract][Full Text] [Related]
8. Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by
Yang J; Jones MS; Ramos RI; Chan AA; Lee AF; Foshag LJ; Sieling PA; Faries MB; Lee DJ
Front Oncol; 2017; 7():61. PubMed ID: 28424760
[No Abstract] [Full Text] [Related]
9. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
10. Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma.
Song H; Huang P; Niu J; Shi G; Zhang C; Kong D; Wang W
Biomaterials; 2018 Mar; 159():119-129. PubMed ID: 29324304
[TBL] [Abstract][Full Text] [Related]
11. A Novel
Zhang L; Du J; Song Q; Zhang C; Wu X
J Immunol Res; 2022; 2022():1178874. PubMed ID: 35155685
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
13. Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy.
Yang A; Bai Y; Dong X; Ma T; Zhu D; Mei L; Lv F
Acta Biomater; 2021 Oct; 133():257-267. PubMed ID: 34407475
[TBL] [Abstract][Full Text] [Related]
14. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
15. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
16. Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung.
Moreo E; Jarit-Cabanillas A; Robles-Vera I; Uranga S; Guerrero C; Gómez AB; Mata-Martínez P; Minute L; Araujo-Voces M; Felgueres MJ; Esteso G; Uranga-Murillo I; Arias M; Pardo J; Martín C; Valés-Gómez M; Del Fresno C; Sancho D; Aguiló N
Nat Commun; 2023 Oct; 14(1):6090. PubMed ID: 37794033
[TBL] [Abstract][Full Text] [Related]
17. IL-32γ potentiates tumor immunity in melanoma.
Gruber T; Kremenovic M; Sadozai H; Rombini N; Baeriswyl L; Maibach F; Modlin RL; Gilliet M; von Werdt D; Hunger RE; Seyed Jafari SM; Parisi G; Abril-Rodriguez G; Ribas A; Schenk M
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32841222
[TBL] [Abstract][Full Text] [Related]
18. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
19. Accelerated induction of mycobacterial antigen-specific CD8+ T cells in the Mycobacterium tuberculosis-infected lung by subcutaneous vaccination with Mycobacterium bovis bacille Calmette-Guérin.
Begum D; Umemura M; Yahagi A; Okamoto Y; Hamada S; Oshiro K; Matsuzaki G
Immunology; 2009 Dec; 128(4):556-63. PubMed ID: 19930045
[TBL] [Abstract][Full Text] [Related]
20. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
